Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Oliver & Co who wrote (3279)	12/10/1997 9:43:00 PM
From: Oliver & Co	Read Replies (2) \| Respond to of 6136

"AIDS Drugs-for-the-Poor Plan to Start Early 1998" Reuters (12/10/97); Bunce, Matthew ÿÿÿÿ The UNAIDS Drug Access Initiative, a controversial pilot project starting next year, seeks to encourage pharmaceutical companies to reduce their prices for expensive anti-retroviral drugs against HIV.ÿ The project will bring less expensive drugs to Africa in January, but some critics say that the money could be better spent on the development of a vaccine against HIV. According to Seth Berkley, president of the International AIDS Vaccine Initiative, less than $200 million is spent annually on vaccine research and less than $50 million a year on vaccine development.ÿ That small amount of money, Berkley adds, represents just 1 percent of the total amount spent on AIDS worldwide.